10.1002/chem.201705670
Chemistry - A European Journal
FULL PAPER
Chiarugi Brain Behav. Immun. 2015, 50, 78. b) S. Ladisch, R. Li, E. Olson,
Proc. Natl. Acad. Sci. U. S. A.,1994, 91, 1974.
[7] a) Y. Gao, X. He, F. Ding, Y. Zhang, Synthesis, 2016, 48, 4017. b) M.
Martinková, J. Gonda, D. Jacková, D. Tetrahedron: Asymmetry 2016, 27,
1187. b) J. A. Morales-Serna, J. Llaveria, Y. Díaz, M. I. Matheu, S.
Castillon, Curr. Org. Chem. 2010, 14, 2483.
[8] T. J. Donohoe, A. Flores, A. R. Lacy, A. H. Rathi, Chem. Eur. J. 2011, 17,
58.
[9] D. Leonori, P. H. Seeberger, Org. Lett. 2012, 14, 4954.
[10] a) T. J. Donohoe, C. J. R. Bataille, W. Gattrell, J. Kloesges, E. Rossignol,
Org. Lett. 2007, 9, 1725. b) T. J. Donohoe, P. D. Johnson, M. Helliwell, M.
Keenan, Chem. Commun. 2001, 2078.
(0.11 mmol) were subsequently added. The resulting mixture was kept at
0ºC for one hour and then warmed to room temperature. After completion,
the crude was concentrated under reduced pressure.
General procedure for the cross metathesis of alkenyl
oxazolidinones with terminal olefins. A two-neck round-bottom flask
fitted with a reflux condenser was charged with a solution of alkenyl
oxazolidinone (0.10 mmol) in dry dichloromethane (0.05 M). Terminal
olefin (0.12 mmol) and Grubbs catalyst 2nd generation (5 mol%) were then
added and the reaction mixture was stirred at 40ºC for 24 h. After
completion, the crude was concentrated under reduced pressure.
[11] J. Guasch, Y. Díaz, M. I. Matheu, S. Castillon, Chem. Commun. 2014, 50,
Computational Details. All the calculations were carried out using
Gaussian09 (Rev. D01)[35] at the M062X level of theory.[36] All the
structures were optimized in solution using the SMD implicit solvation
method,[37] with chloroform as solvent (ε = 4.7113). For optimizations and
frequency calculations we used the standard basis set 6-31G(d).[38]
Potential energies were further refined using the basis set 6-
311++G(d,p).[39] This methodology has been proved to provide accurate
results on similar systems.[40]
7344.
[12] a) H. Ohno, Chem. Rev. 2014, 114, 7784. b) G. Deguirez, U. Pons, P.
Dauban, Angew. Chem. Int. Ed. 2012, 51, 7384. c) H. Pellissier,
Tetrahedron 2010, 66, 1509. d) J. Ciesielsky, G. Dequirez, P. Retailleau, V.
Gandon, P. Dauban, Chem. Eur. J. 2016, 22, 9338. e) W. P. Unsworth, S.
G. Lamont, J. Robertson, Tetrahedron 2014, 70, 7388. f) W. P. Unsworth,
N. Clark, T. O. Ronson, K. Stevens, A. L. Thompson, S. G. Lamont, J
Robertson, Chem. Commun. 2014, 50, 11393. g) R. Bodner, B. K.
Marcellino, A. Severino, A. L. Smenton, C. M. Rojas J. Org. Chem. 2005,
70, 3988. h) A. Padwa, A. C, Flick, C. A. Leverett, T. Stengel, J. Org. Chem.
2004, 69, 6377.
[13] For an intermolecular synthesis of vinylaziridines through an intermolecular
process see: a) J. Llaveria, A. Beltrán, M. M. Díaz-Requejo, M. I. Matheu,
S. Castillon, P. J. Pérez, Angew. Chem Int. Ed. 2010, 49, 7092. b) J.
Llaveria, A. Beltrán, W. M. C. Sameera, A. Locati, M. M. Díaz-Requejo, M.
I Matheu, S. Castillon, F. Maseras, P. J. Pꢀrez, J. Am. Chem. Soc. 2014,
136, 5342.
All the stationary points were assigned to minima or transition states by
frequency analyses (zero imaginary frequencies for minima and one for
transition states). All the energies reported in the manuscript are free
energies in solution calculated at 298 K and 1 atm in kcal/mol. Due to the
flexibility of the system and the importance of conformation analysis in this
type of calculations,[41] a conformational analysis of key transition states
i
were done. In addition, PrCOO- was replaced by AcO- to simplify the
conformational search, as it was done in previous studies.[40] A data set
collection of computational results is available in IoChem-BD repository.[42]
[14] For a silver-catalyzed asymmetric aziridination of homoallyl carbamates
see: M. Ju, C. D. Weatherly, I. A. Guzei, J. M. Schomaker, Angew. Chem.
Int. Ed. 2017, 56, 9944.
[15] For reviews see: a) P. Doyle J. Org. Chem. 2006, 71, 9253. b) J. Hansen,
H. M. L. Davies, Coord. Chem. Rev. 2008, 252, 545. c) M. El-Deftar, R. G.
Adly, M. G. Gardiner, A. Chanem, Curr. Org. Chem. 2012, 16, 1808. d) F.
G. Adly, A. Ghanem, Chirality 2014, 26, 692. e) Y. Deng, H. Qiu, H. D.
Srinivas, M. P. Doyle, Curr.Org. Chem. 2016, 20, 61. f) G. Dequirez, V.
Pons, Ph. Dauban, Angew. Chem. Int. Ed. 2012, 51, 7384.
[16] Good enantioselectivities in cyclization of indol containing carbamates
have been reported: a) (Rh(II)): S. Sato, M. Shibuya, N. Kanoh, Y.
Iwabuchi, Chem. Commun. 2009, 6264. b) (Fe(II)): Y-Q. Zhang, Y-A. Yuan,
G-S. Liu, H. Xu. Org. Lett. 2013, 15, 3910.
[17] Rh(II)-catalyzed asymmetric aziridination of homoallyl carbamates afforded
ee<23%. C. J. Hayes, P. W. Beavis, L. A. Humphries, Chem. Commun.
2006, 4501.
[18] a) X. Yang, V. D. Bumbu, Liu, X. Li, H. Jiang, E. W. Uffman, L. Guo, W.
Zhang, X. Jiang, K. N. Houk, V. B. Birman, J. Am. Chem. Soc. 2012, 134,
17605. b) V. B. Birman, H. Jiang, X. Li, L. Guo, E. W. Uffman, J. Am. Chem.
Soc. 2006, 128, 6536.
Acknowledgements
Financial support by the Ministerio de Economia y Competividad
(Mineco), Spain (CTQ2014-58664-R) and the European Regional
Development Fund are gratefully acknowledged. J.G. thanks
Generalitat de Catalunya for a FI fellowship and I.G-N. Mineco for
a predoctoral FPI fellowship (Ref: BES-2015-074435). F.M. and
I.F-A. thank the financial support from the CERCA
Programme/Generalitat de Catalunya and MINECO (Project
CTQ2014-57661-R and Severo Ochoa Excellence Accreditation
2014–2018 SEV-2013-0319). I.F-A thanks the Severo Ochoa
predoctoral training fellowship (Ref: SVP-2014-068662).
[19] For a recent review by Birman see: V. B. Birman, Aldrichimica Acta, 2016,
49, 23.
[20] For more general reviews see: a) P. Somfai, Angew. Chem. Int. Ed. 1997,
36, 2731. b) S. France, D. J. Guerin, S. J. Miller, T. Lectka, T. Chem. Rev.
2003, 103, 2985. c) E. Vedejs, M. Jure, M. Angew. Chem. Int. Ed. 2005,
44, 3974. d) J. E. Taylor, S. D. Bull, J. M. Williams, Chem. Soc. Rev. 2012,
41, 2109.
Conflict of interest
The authors declare no conflict of interest
[21] X. Li, P. Liu, K. N. Houk, V. B. Birman, J. Am. Chem. Soc. 2008, 130,
13836.
[22] For reviews see: a) Q. Peng, F. Duarte, R. S. Paton, Chem. Soc. Rev.
2016, 45, 6093. b) P. H.-Y. Cheong, C. Y. Legault, J. M. Um, N. Çelebi-
Ölçum, K. N. Houk, Chem. Rev. 2011, 111, 5042.
Keywords: kinetic resolution • organocatalysis • ABC catalysts •
oxyamination • enantioselectivity
[23] C. Liu, M. Besora, F. Maseras, Chem. Asian. J. 2016, 11, 411.
[24] I. Funes-Ardoiz, W. M. C. Sameera, R. M. Romero, C. Martínez, J. A.
Souto, D. Sampedro, K. Muñiz, F. Maseras, Chem. Eur. J. 2016, 22,
7545.
[25] L. Dell’Amico, V. M. Fernández-Álvarez, F. Maseras, P. Melchiorre,
Angew. Chem. Int. Ed. 2017, 56, 3304.
[1] S. T. Pruett, A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C.
Sullards, D. C. Liotta, A. H. Merrill Jr, Lipid Res. 2008, 49, 1621.
[2] Review de clavavinol a) T. V. Kumar- Reddy, A. Jyotsna, B. L. A.
Prabhavathi-Devi, R. B. N. Prasad, Y. Poornachandra, C. G. Kumar, Eur.
J. Med. Chem. 2016, 120, 86. b) A. Aiello, E. Fattorusso, A. Giordano, M.
Menna, C. Navarrete, E. Muñoz, Tetrahedron, 2009, 65, 4384.
[26] a) V. B. Birman, E. W. Uffman, H. Jiang, X. Li, C. J. Kilbane, J. Am. Chem.
Soc. 2004, 126, 12226. b) V. B. Birman, H. Jiang, Org. Lett. 2005, 7, 3445.
c) V. B. Birman, X. Li, Org. Lett. 2006, 8, 1351.
[3] a) A. Dyckman J. Med. Chem. 2017, doi: 10.1021/acs.jmedchem.6b01575.
b) M. Wymann, R.; Schneiter, Nat. Rev. Mol. Cell Biol. 2008, 9, 162. c) Y.
A. Hannun, R. M. Bell, Science 1989, 243, 500. d) Y. A. Hannun, in:
Sphingolipid-mediated Signal Transduction, Y. A. Hannun (Ed.), R.G.
Landes Comp. and Chapman & Hall, New York, 1997.
[27] Kinetic resolution performed on regioisomeric products 2b-4b proceeded
with very low conversions.
[28] V. B. Birman, X. Li, Org. Lett. 2008, 10, 1115.
[29] Leonori, D.; Seeberger, P. H. Org. Lett. 2012, 14, 4954.
[4] a) The Role of Sphingolipids in Cancer Development and Therapy. Adv.
Cancer Res., vol 117, J. S. Norris,. Ed., Academic Press, 2013. b) J.
Newton, S. Lima, M. Maceyka, S. Spiegel, Exp. Cell Res. 2015, 333, 195.
c) C. Huang, C. Freter Int. J. Mol. Sci. 2015, 16, 924.
[5] L. M. Healy, J. P. Antel, Curr. Drug Targets 2016, 17, 1841.
[6] a) L. Cavone, R. Felici, A. Lapucci, D. Buonvicino, S. Pratesi, M. Muzzi, B.
Hakiki, L. Maggi, B. Peruzzi, R. Caporale, F. Annunciato, M. P. Amato, A.
[30] Abad, J. L.; Nieves, I.; Rayo, P.; Casas, J.; Fabriàs, G.; Delgado, A. J.
Org. Chem. 2013, 78, 5858.
[31] Related compounds called ceramides have shown anticancer activity. A.
Sing, H-J. Ha, J. Park, H. J. Kim, H. J. Lee, Bioorg. Med. Chem. 2011, 19,
6174.
This article is protected by copyright. All rights reserved.